Equities Analysts Set Expectations for Imunon, Inc.’s Q1 2024 Earnings (NASDAQ:IMNN)

Imunon, Inc. (NASDAQ:IMNNFree Report) – Investment analysts at Brookline Capital Management issued their Q1 2024 EPS estimates for Imunon in a report released on Sunday, March 31st. Brookline Capital Management analyst K. Dolliver expects that the company will earn ($0.48) per share for the quarter. The consensus estimate for Imunon’s current full-year earnings is ($1.95) per share. Brookline Capital Management also issued estimates for Imunon’s Q2 2024 earnings at ($0.50) EPS, Q3 2024 earnings at ($0.46) EPS and Q4 2024 earnings at ($0.50) EPS.

Separately, HC Wainwright increased their price objective on shares of Imunon from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday.

Check Out Our Latest Stock Report on Imunon

Imunon Stock Down 9.3 %

IMNN stock opened at $1.75 on Tuesday. Imunon has a 52 week low of $0.48 and a 52 week high of $2.00. The company has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $0.87. The firm has a market capitalization of $16.45 million, a P/E ratio of -0.80 and a beta of 2.02.

Hedge Funds Weigh In On Imunon

Several institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its position in Imunon by 20.1% during the second quarter. Renaissance Technologies LLC now owns 74,011 shares of the company’s stock valued at $95,000 after purchasing an additional 12,400 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Imunon in the 1st quarter worth about $83,000. Finally, Geode Capital Management LLC bought a new stake in shares of Imunon in the 1st quarter worth about $62,000. Institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

(Get Free Report)

Imunon, Inc, a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma.

See Also

Earnings History and Estimates for Imunon (NASDAQ:IMNN)

Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.